Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | RORA | P35398 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | RORB | Q92753 | 1/20 | 0.36 |
| ▸ | TYR | P14679 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15043714 | 0.85 | ALDH1A1 (0.41) | LMNASMN1; SMN2NPC1MITFTP53 | |
| SCHEMBL16418588 | 0.84 | LMNA (0.40) | LMNASMN1; SMN2NPC1MITFTP53 | |
| SCHEMBL10223611 | 0.81 | KCNH2 (0.40) | LMNASMN1; SMN2NPC1MITFTP53 | |
| SCHEMBL15043720 | 0.79 | LMNA (0.39) | LMNASMN1; SMN2NPC1MITFTP53 | |
| SCHEMBL16418594 | 0.76 | PTGDR2 (0.40) | LMNASMN1; SMN2NPC1MITFTP53 | |
| SCHEMBL15043718 | 0.76 | TP53 (0.37) | LMNASMN1; SMN2NPC1MITFTP53 | |
| SCHEMBL15470656 | 0.76 | LMNA (0.37) | LMNASMN1; SMN2NPC1MITFTP53 | |
| SCHEMBL16418601 | 0.75 | ALDH1A1 (0.62) | LMNASMN1; SMN2NPC1TP53RAB9A | |
| SCHEMBL13384524 | 0.74 | MAPT (0.37) | LMNASMN1; SMN2NPC1TP53RAB9A | |
| SCHEMBL783280 | 0.74 | CCR9 (0.39) | LMNASMN1; SMN2NPC1MITFTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096527-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-8952009-B2 | Chroman derivatives as TRPM8 inhibitors | AMGEN INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC (US) | 2015-01-29 | — | — | US | disclosed |
| US-20140171406-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171639-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-8710043-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20140045855-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20130157996-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-7759356-B2 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-07-20 | — | — | US | disclosed |
| US-7754730-B2 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754730-B2 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20090054429-A1 | ARYLINDENOPYRIDINES AND ARYLINDENOPYRIMIDINES AND RELATED THERAPEUTIC AND PROPHYLACTIC METHODS | JANSSEN PHARMACEUTICA NV (BE) | 2009-02-26 | — | — | US | disclosed |
| US-7468373-B2 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7468373-B2 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7345052-B2 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20070155760-A1 | ARYLINDENOPYRIDINES AND ARYLINDENOPYRIMIDINES AND RELATED THERAPEUTIC AND PROPHYLACTIC METHODS | JANSSEN PHARMACEUTICA NV (BE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155760-A1 | ARYLINDENOPYRIDINES AND ARYLINDENOPYRIMIDINES AND RELATED THERAPEUTIC AND PROPHYLACTIC METHODS | JANSSEN PHARMACEUTICA NV (BE) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | TRPM8, TRPM5, TRPM7 | LMNA 710/4885SMN1; SMN2 923/4885NPC1 702/4885 |
| US-20070155760-A1 | ARYLINDENOPYRIDINES AND ARYLINDENOPYRIMIDINES AND RELATED THERAPEUTIC AND PROPHYLACTIC METHODS | ADORA2A, ADORA1, ADORA3 | LMNA 3596/4885SMN1; SMN2 3498/4885NPC1 2727/4885 |
| US-20140045855-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | TRPM8, TRPM5, TRPM7 | LMNA 710/4885SMN1; SMN2 923/4885NPC1 702/4885 |
| US-20140171639-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | LMNA 1221/4885SMN1; SMN2 837/4885NPC1 533/4885 |
| US-20140171406-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | LMNA 1221/4885SMN1; SMN2 837/4885NPC1 533/4885 |
| US-20130157996-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | LMNA 1221/4885SMN1; SMN2 837/4885NPC1 533/4885 |
| US-20090054429-A1 | ARYLINDENOPYRIDINES AND ARYLINDENOPYRIMIDINES AND RELATED THERAPEUTIC AND PROPHYLACTIC METHODS | ADORA2A, ADORA1, ADORA3 | LMNA 3596/4885SMN1; SMN2 3498/4885NPC1 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.